These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34658954)
41. Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Sodhi DK; Hagerman R Pharmgenomics Pers Med; 2021; 14():1689-1699. PubMed ID: 35002287 [TBL] [Abstract][Full Text] [Related]
42. Gait and Functional Mobility Deficits in Fragile X-Associated Tremor/Ataxia Syndrome. O'Keefe JA; Robertson-Dick EE; Hall DA; Berry-Kravis E Cerebellum; 2016 Aug; 15(4):475-82. PubMed ID: 26298472 [TBL] [Abstract][Full Text] [Related]
43. Prevalence and predictors of subjective memory complaints in adult male carriers of the FMR1 premutation. Birch RC; Hocking DR; Trollor JN Clin Neuropsychol; 2016 Aug; 30(6):834-48. PubMed ID: 27355815 [TBL] [Abstract][Full Text] [Related]
44. Fragile x-associated premature ovarian failure in a large Turkish cohort: Findings of Hacettepe Fragile X Registry. Utine GE; Şimşek-Kiper PÖ; Akgün-Doğan Ö; Ürel-Demir G; Alanay Y; Aktaş D; Boduroğlu K; Tunçbilek E; Alikaşifoğlu M Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():76-80. PubMed ID: 29275276 [TBL] [Abstract][Full Text] [Related]
45. Blood expression profiles of fragile X premutation carriers identify candidate genes involved in neurodegenerative and infertility phenotypes. Mateu-Huertas E; Rodriguez-Revenga L; Alvarez-Mora MI; Madrigal I; Willemsen R; Milà M; Martí E; Estivill X Neurobiol Dis; 2014 May; 65():43-54. PubMed ID: 24418349 [TBL] [Abstract][Full Text] [Related]
46. Fragile X associated neuropsychiatric disorders in a male without FXTAS. Cabal-Herrera AM; Saldarriaga-Gil W; Salcedo-Arellano MJ; Hagerman RJ Intractable Rare Dis Res; 2020 May; 9(2):113-118. PubMed ID: 32494560 [TBL] [Abstract][Full Text] [Related]
47. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Rodriguez-Revenga L; Madrigal I; Pagonabarraga J; Xunclà M; Badenas C; Kulisevsky J; Gomez B; Milà M Eur J Hum Genet; 2009 Oct; 17(10):1359-62. PubMed ID: 19367323 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of FMR4, FMR5 and FMR6 Expression Levels as Non-Invasive Biomarkers for the Diagnosis of Fragile X-Associated Primary Ovarian Insufficiency (FXPOI). Alvarez-Mora MI; Agusti I; Wijngaard R; Martinez-Barrios E; Barcos T; Borras A; Peralta S; Guimera M; Goday A; Manau D; Rodriguez-Revenga L J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456280 [TBL] [Abstract][Full Text] [Related]
49. Fragile X syndrome: An overview and update of the FMR1 gene. Mila M; Alvarez-Mora MI; Madrigal I; Rodriguez-Revenga L Clin Genet; 2018 Feb; 93(2):197-205. PubMed ID: 28617938 [TBL] [Abstract][Full Text] [Related]
50. Screening for the FMR1 premutation in Greek patients with late-onset movement disorders. Kartanou C; Seferiadi M; Pomoni S; Potagas C; Sofocleous C; Traeger-Synodinos J; Stefanis L; Panas M; Koutsis G; Karadima G Parkinsonism Relat Disord; 2023 Feb; 107():105253. PubMed ID: 36549234 [TBL] [Abstract][Full Text] [Related]
51. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Hamlin AA; Sukharev D; Campos L; Mu Y; Tassone F; Hessl D; Nguyen DV; Loesch D; Hagerman RJ Am J Med Genet A; 2012 Jun; 158A(6):1304-9. PubMed ID: 22528549 [TBL] [Abstract][Full Text] [Related]
52. Health problems in females carriers of premutation in the FMR1 gene. Lisik MZ Psychiatr Pol; 2017 Oct; 51(5):899-907. PubMed ID: 29289969 [TBL] [Abstract][Full Text] [Related]
53. Immune mediated disorders in women with a fragile X expansion and FXTAS. Jalnapurkar I; Rafika N; Tassone F; Hagerman R Am J Med Genet A; 2015 Jan; 167A(1):190-7. PubMed ID: 25399540 [TBL] [Abstract][Full Text] [Related]
54. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. Jacquemont S; Hagerman RJ; Leehey MA; Hall DA; Levine RA; Brunberg JA; Zhang L; Jardini T; Gane LW; Harris SW; Herman K; Grigsby J; Greco CM; Berry-Kravis E; Tassone F; Hagerman PJ JAMA; 2004 Jan; 291(4):460-9. PubMed ID: 14747503 [TBL] [Abstract][Full Text] [Related]
55. The diagnostic experience of women with fragile X-associated primary ovarian insufficiency (FXPOI). Poteet B; Ali N; Bellcross C; Sherman SL; Espinel W; Hipp H; Allen EG J Assist Reprod Genet; 2023 Jan; 40(1):179-190. PubMed ID: 36447079 [TBL] [Abstract][Full Text] [Related]
56. FXPOI: Pattern of AGG Interruptions Does not Show an Association With Age at Amenorrhea Among Women With a Premutation. Allen EG; Glicksman A; Tortora N; Charen K; He W; Amin A; Hipp H; Shubeck L; Nolin SL; Sherman SL Front Genet; 2018; 9():292. PubMed ID: 30123240 [TBL] [Abstract][Full Text] [Related]
57. [Heterogeneity of clinical characteristics of FMR1-related disorders]. Pereverzeva DS; Tyushkevich SA; Gorbachevskaya NL; Mamokhina UA; Danilina KK Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(7):103-111. PubMed ID: 31464297 [TBL] [Abstract][Full Text] [Related]
58. Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. De Caro JJ; Dominguez C; Sherman SL Ann N Y Acad Sci; 2008; 1135():99-111. PubMed ID: 18574214 [TBL] [Abstract][Full Text] [Related]
59. A methylation PCR method determines Hadd AG; Filipovic-Sadic S; Zhou L; Williams A; Latham GJ; Berry-Kravis E; Hall DA Clin Epigenetics; 2016; 8():130. PubMed ID: 27980694 [TBL] [Abstract][Full Text] [Related]